WHO gives nod to Biological E as additional production site for JnJ COVID vaccine

India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.

Published On 2022-06-23 11:00 GMT | Update On 2024-02-15 17:59 GMT

New Delhi: Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine. "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and...

New Delhi: Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.

"Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday.

India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.

CORBEVAX is a protein sub-unit vaccine, developed from a component of the spike protein on the virus's surface, which helps the body build the immune response against the virus. The vaccine has the Receptor Binding Domain (RBD) protein as an antigen, CpG 1018 and Aluminium hydroxide as adjuvants formulated in Tris buffer.

Read also: Biological E Corbevax price slashed to Rs 250 a dose

The Drugs Controller General of India (DCGI) recently approved Corbevax as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination (two doses) of COVAXIN or COVISHIELD vaccines for restricted use in emergency situation.

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics.

BE supplies its vaccines to more than 130 countries and its therapeutic products are sold in India and the USA, Europe. BE currently has 8 WHO-prequalified vaccines in its portfolio and 5 USFDA approved Injectables.

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

WHO gives nod to Biological E as additional production site for JnJ COVID vaccine

India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.

Similar News